Clinical Trials Directory

Trials / Completed

CompletedNCT01162603

Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)

Comparative Evaluation of Intraocular Pressure During the 24 Hour in Patients Affected by Primary Open-angle Glaucoma and Ocular Hypertension: Latanoprost 0.005% Versus Tafluprost 0.0015% Ophthalmic Solutions

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Academic / Other
Sex
All
Age
45 Years
Healthy volunteers
Not accepted

Summary

* Main objective is to compare the ability of Latanoprost 0.005% preservative-added ophthalmic solution versus Tafluprost 0.0015% preservative-free ophthalmic solution, both given once a day at the evening, in reducing 24-hour intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. First efficacy variable will be the difference between mean nocturnal IOP values after three months of treatment: nocturnal IOP is defined as the mean value between 2AM and 6AM measurements. * Secondary objectives will be the comparison between Latanoprost 0.005% and Tafluprost 0.0015% ophthalmic solution about: * Mean 24-hour IOP values after three months of treatment * IOP values at these time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment

Conditions

Interventions

TypeNameDescription
DEVICEGoldmann and Perkins applanation tonometryIOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
DRUGTAFLUPROST 0.0015% EYEDROPSTafluprost 0.0015% preservative-free ophthalmic solution
DRUGLATANOPROST 0.005% EYEDROPSLatanoprost 0.005% preservative-added ophthalmic solution

Timeline

Start date
2011-03-01
Primary completion
2012-04-01
Completion
2012-04-01
First posted
2010-07-14
Last updated
2013-05-07

Locations

2 sites across 2 countries: Greece, Italy

Source: ClinicalTrials.gov record NCT01162603. Inclusion in this directory is not an endorsement.